Ligand Pharmaceuticals | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Amgen USD 5.97B 781M 2024-12
Arrowhead Research -173085000 2.55M 2024-12
Baxter International USD 1.02B 19M 2024-12
Bristol-Myers Squibb USD 9.13B 94M 2024-12
Eli Lilly USD 11.13B 1.86B 2024-12
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.56B 57M 2024-12
Glaxosmithkline GBP 5.6B 94M 2024-12
Insmed USD 78.29M 6.04M 2024-12
Ionis Pharmaceuticals USD 222.75M 90M 2024-12
Ligand Pharmaceuticals USD 39.98M 9.39M 2024-12
MacroGenics USD 13.86M 94.98M 2024-12
Merck USD 11.92B 852M 2024-12
Pacira USD 147.37M 17.66M 2024-12
Pfizer USD 12.11B 718M 2024-12
Veracyte USD 78.75M 256K 2024-12



Ligand Pharmaceuticals Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.